{
    "organizations": [],
    "uuid": "1da3a1ee7831bcdca6b7f3885d54493715cda1bd",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-nightstar-therapeutics-starts-star/brief-nightstar-therapeutics-starts-star-phase-3-registrational-trial-for-nsr-rep1-in-choroideremia-idUSASB0C8P6",
    "ord_in_thread": 0,
    "title": "BRIEF-Nightstar Therapeutics Starts Star Phase 3 Registrational Trial For Nsr-Rep1 In Choroideremia",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 5 (Reuters) - Nightstar Therapeutics Plc:\n* NIGHTSTAR THERAPEUTICS ANNOUNCES INITIATION OF STAR PHASE 3 REGISTRATIONAL TRIAL FOR NSR-REP1 IN CHOROIDEREMIA\n* NIGHTSTAR THERAPEUTICS - STAR TRIAL EXPECTED TO ENROLL APPROXIMATELY 140 PATIENTS ACROSS 18 CLINICAL SITES Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-05T19:51:00.000+02:00",
    "crawled": "2018-03-06T22:15:46.030+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "nightstar",
        "therapeutic",
        "plc",
        "nightstar",
        "therapeutic",
        "announces",
        "initiation",
        "star",
        "phase",
        "registrational",
        "trial",
        "choroideremia",
        "nightstar",
        "therapeutic",
        "star",
        "trial",
        "expected",
        "enroll",
        "approximately",
        "patient",
        "across",
        "clinical",
        "site",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}